Sprint Bioscience AB (publ) (STO:SPRINT)
Sweden · Delayed Price · Currency is SEK 1.920
+0.060 (3.23%)
At close: Mar 4, 2026
Sprint Bioscience AB Revenue
In the year 2025, Sprint Bioscience AB had annual revenue of 167.17M SEK with 152.74% growth. Sprint Bioscience AB had revenue of 133.91M in the quarter ending December 31, 2025, with 698.65% growth.
Revenue
167.17M
Revenue Growth
+152.74%
P/S Ratio
1.21
Revenue / Employee
5.57M
Employees
30
Market Cap
202.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 167.17M | 101.03M | 152.74% |
| Dec 31, 2024 | 66.14M | 14.46M | 27.97% |
| Dec 31, 2023 | 51.69M | 51.60M | 62,171.08% |
| Dec 31, 2022 | 83.00K | -34.95M | -99.76% |
| Dec 31, 2021 | 35.03M | 15.83M | 82.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 300.49M |
| Bio-Works Technologies AB | 63.11M |
| IRLAB Therapeutics AB | 57.46M |
| Intervacc AB | 20.09M |
| NextCell Pharma AB | 11.06M |
| Simris Group AB (PUBL) | 3.40M |
| Xintela AB | 2.28M |
| Mendus AB | -1.44M |